Leukemic transformation in patients with 5Q- and additional abnormalities.

Area of Science:

• Hematology
• Cytogenetics
• Oncology

Background:

• Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
• The 5q- marker is a specific chromosomal abnormality observed in MDS.
• Understanding the prognostic implications of chromosomal abnormalities in MDS is crucial for patient management.

Purpose of the Study:

• To investigate the relationship between the 5q- marker, with or without additional chromosomal abnormalities, and the clinical evolution of myelodysplastic syndromes.
• To assess the prognostic value of cytogenetic findings in MDS patients.

Main Methods:

• Analysis of 12 myelodysplastic syndrome patients (6 males, 6 females).
• Classification of patients based on subtypes: refractory anemia (RA), RA with ring sideroblasts (RA-S), RA with excess of blasts (RAEB), and RAEB in transformation (RAEB-T).
• Cytogenetic analysis using G-banding on bone marrow cells at diagnosis, with a 50-month follow-up.

Main Results:

• Five patients with a single 5q- marker (3 RA, 2 RA-S) exhibited prolonged survival without progression to leukemia.
• MDS patients with the 5q- marker and additional chromosomal abnormalities (del(12p), del(7q), del(14q), i(11q), i(17q)) showed rapid neoplastic evolution.
• Cytogenetic complexity correlated with adverse clinical outcomes.

Conclusions:

• The 5q- marker as the sole abnormality in MDS is associated with a favorable prognosis.
• The presence of additional chromosomal abnormalities alongside the 5q- marker significantly increases the risk of leukemic transformation.
• Cytogenetic analysis is a valuable tool for predicting the clinical course and prognosis in myelodysplastic syndromes.